Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Denmark

Research and Innovation Action · Running

PREMIO COLLAB Personalised response monitoring in oncology: co-creating clinical trials in advanced breast cancer

Coordinator
Region Syddanmark, Denmark
Runs
1 January 2024 to 31 December 2029
Status
Running
EU funding
€7.5m
Total cost
€7.5m
Partners
16 organisations in 7 countries
Type
Research and Innovation Action
Grant agreement
101136812

What the project is doing

In the project's own words, from its summary on CORDIS.

PREMIO COLLAB’s vision is to prolong overall survival and improve the quality of life for patients with metastatic breast cancer (MBC) by providing refined guidance for managing response monitoring. PREMIO COLLAB strives to facilitate improved patient care and streamlined clinical workflows addressing the needs of patients, healthcare professionals, and society. Response evaluation methods for patients with MBC have not been modernised for decades, although molecular imaging with FDG-PET/CT has emerged as a highly accurate method for staging MBC, and staging and monitoring MBC has a profound influence on treatment options and the chances of survival.

Furthermore, the patient perspective has rarely been considered, although continuous response evaluation in a monitoring setting has interacted with the life of MBC patients for years. Still, no specific recommendations are provided internationally for response evaluation in MBC or in the overall management of monitoring. PREMIO COLLAB offers complementary competencies in an interdisciplinary collaborative effort to lift this complex task.

In a pragmatic multicenter randomised clinical trial (RCT), we will apply the intervention of FDG-PET/CT-based monitoring and compare it with conventional CT as state-of-the-art. The objectives are to analyse the impact of the intervention on overall survival and quality of life in patients with MBC and include cost-effectiveness analyses directly informing HTA agencies and health policymakers. Building on knowledge from the RCT, we will use participatory research designs to develop improved and modernised patient pathways and digital workflows.

AI-based solutions in imaging and liquid biopsies constitute perspectives with a broader horizon. The work will be done in multiple European centres and living labs with patient representatives, clinicians, and relevant stakeholders aiming to provide knowledge for updated recommendations with a view to subsequent clinical implementation. This action is part of the Cancer Mission cluster of projects on ‘‘Diagnostics and Treatment (diagnostics).”

Topics

Who is involved

OrganisationCityCountryRole
Region SyddanmarkVejleDenmarkCoordinator
Umit Tirol - Private Universitat Fur Gesundheitswissenschaften Und Technologie GmbHHall In TyrolAustriaParticipant
Universite De GeneveGeneveSwitzerlandAssociatedpartner
Klinikum Der Technischen Universität München (tum Klinikum)MuenchenGermanyParticipant
Universitaet MuensterMuensterGermanyParticipant
Universitaetsklinikum EssenEssenGermanyParticipant
Aarhus UniversitetshospitalAarhusDenmarkParticipant
Region HovedstadenHillerodDenmarkParticipant
Region Nordjylland (north Denmark Region)AalborgDenmarkParticipant
Syddansk UniversitetOdense MDenmarkParticipant
Alma Mater Studiorum - Universita Di BolognaBolognaItalyParticipant
Humanitas Mirasole SpARozzano (Mi)ItalyParticipant
Irccs Azienda Ospedaliero- Universitaria Di BolognaBolognaItalyParticipant
Istituto Nazionale Oncologico CandioloCandioloItalyParticipant
Research Consortium for Medical Image AnalysisLundSwedenParticipant
University of StrathclydeGlasgowUnited KingdomAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI